GH Research: 'Buy' GH001 TRD Advancement Presses On And Expansion Opportunities

Summary I initiate coverage on GH Research PLC with a "Buy" rating, driven by renewed momentum in its GH001 program for treatment-resistant depression [TRD]. The company resolved the FDA clinical hold on its IND for GH001, positioning it for a pivotal phase 3 TRD trial expected to start in 2026. GH001 demonstrates competitive advantages: shortest-acting psychedelic [11-minute psychoactive phase] and reduced treatment visits versus SPRAVATO and BPL-003. Positive proof-of-concept data in postpartum depression and Bipolar 2 Disorder expand GH001’s potential, but financial runway and dilution risk remain key considerations. Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More » Nansan Houn/iStock via Getty Images I'm initiating coverage on GH Research PLC ( GHRS ) with a "Buy" rating. The reason why I'm doing so is because the company has been able to get its program of using its formulated inhalation version This article was written by Terry Chrisomalis 15.17K Followers Follow Terry Chrisomalis is a private investor in the Biotech sector with years of experience utilizing his Applied Science background to generate long term value from Healthcare. He is the author of the investing group Biotech Analysis Central which contains a library of 600+ Biotech investing articles, a model portfolio of 10+ small and mid-cap stocks with deep analysis for each, live chat, and a range of analysis and news reports to help Healthcare investors make informed decisions. Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.